Chairman Address to 2022 Annual General Meeting

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, herein provides the Chairman Address to the 2022 Annual General Meeting (AGM) of shareholders to be held at the at the offices of BDO Australia, Level 9, Mia Yellagonga Tower 2, 5 Spring St, Perth at 3:30pm (WST) today.

Chairman Address

The agenda for the Meeting today will be as follows:

I will start by providing a brief overview of Neurotech, our key highlights from the 2022 financial year, our corporate governance activities and outlook. I will then outline the Meeting procedures and continue to the formal items of business.

Our newest Board member and Executive Director Dr Tom Duthy will then give a short presentation of Neurotech's core development platform, our clinical trials and focused strategic initiatives.

The 2022 financial year was a productive one for Neurotech as we rapidly progressed our core cannabinoid drug candidate, NTI164, which is a proprietary drug formulation derived from a unique cannabis strain with low THC (<0.3%) and a novel combination of cannabinoids including CBDA, CBC, CBDP, CBDB and CBN, into clinical trials. During the financial year period, Neurotech conducted its landmark Phase I/II study in pediatric autism spectrum disorder. The ongoing study has been designed to rigorously assess the safety and efficacy of NTI164 and to evaluate the subject's behaviors, focus and cognitive parameters using validated neuropsychological tools. The very positive results were subsequently reported in July (28 day data) and October (20 week data).

The Company completed a significant amount of pre-clinical work which demonstrated the potent anti-inflammatory and neuro-regulatory activity of NTI164. In parallel, during October 2021, Neurotech filed its first strategic provisional patent applications to underpin future worldwide patent families in respect to this research.

A number of governance and strategic initiatives were implemented after the 2022 financial year and prior to today's meeting.

In August 2022, the Company appointed Dr Tom Duthy as a consultant to the Company with a focus on Investor Relations (IR) and Strategic Corporate Development. On 1 September 2022, the Company appointed Dr Duthy as an Executive Director. Concurrently, I was appointed as Chairman of the Board following the resignations of Neurotech's former Chairman Brian Leedman, and Non-Executive Director Krista Bates, to pursue other corporate interests. We thank both Brian and Krista for their contributions to the Company.

Post those appointments, the new Board has revised and adopted a new strategic plan, that focuses the organisation on pediatric neurological disorders for NTI164 where the scientific literature supports uncontrolled neuroinflammatory processes in children. The company feels these patients may be particularly well-suited to daily oral treatment with NTI164. This focus confers significant advantages to the Company and its shareholders through rapid, cost-effective clinical trials in Australia that

demonstrates the utility of NTI164 and allows Neurotech to potentially capture various regulatory levers available in the United States and Europe, such as orphan drug designations. Our parallel plans seek to receive a US Food and Drug Administration Investigational New Drug (IND) application for NTI164 to conduct a clinical trial in the US.

We have demonstrated a very strong clinical effect for NTI164 in a well-established neuroinflammatory disorder, autism, with both 28 day and 20 week data reported since 30 June 2022. The therapeutic effect of NTI164 on these Level II and Level III Autism Spectrum Disorder patients was strong, which provides Neurotech confidence as we progress to the commencement of a larger, double-blind, placebo-controlled clinical trial during the current quarter.

Based on the 20 week data, and the revised strategic plan, the Company was pleased to conclude a $9 million capital raising to institutional, professional and sophisticated investors. Funds raised under the placement will be applied to the Company's pediatric clinical trials program, including multiple Phase I/II trials in PANDAS/PANS and cerebral palsy, the Phase II/III clinical trial in autism spectrum disorder, drug product manufacturing and scale-up, lead-in pre-clinical work associated with the Company's planned submissions to the US Food and Drug Administration (FDA) to undertake future US trials for NTI164 and general working capital.

We remain committed to our goal of developing NTI164 for the treatment of pediatric neurological disorders, where safe and effective therapies are lacking. The 2023 financial year is shaping up as an incredibly important one for Neurotech and our shareholders, with three important clinical trials in PANDAS/PANS, autism spectrum disorder and cerebral palsy. Additional rare pediatric neurological disorders, where rapid Phase I/II clinical trials can be undertaken, with strong clinician support utilising NTI164 are currently under consideration by the Board.

We would like to extend our thanks to our pediatric patients, their caregivers, our clinicians and their associates along with our service providers that have all played an important role in shaping the success of the business in 2022 and for the foreseeable future. Finally, we would like to extend our thanks to our shareholders, who more recently have supported the Company's focused pediatric strategy with a $9 million capital injection at a difficult time across financial markets generally.

Mr Mark Davies
Chairman

Authority
This announcement has been authorised for release by the Chairman of Neurotech International Limited.

Investors:
Dr Thomas Duthy
Executive Director
td@neurotechinternational.com
+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days and 20 weeks of treatment with NTI164. The Company will commence a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD in Q4 CY2022. Neurotech plans to conduct additional Phase I/II trials in Paediatric Autoimmune Neuropsychiatric

Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with cerebral palsy during CY2023. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech please visit http://www.neurotechinternational.com.